Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 8/20 | 0.46 |
| ▸ | HTR7 | P34969 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135010 | 1.00 | JAK1 (0.48) | JAK1HTR2AHTR7KCNH2DRD2 | |
| SCHEMBL20135089 | 0.94 | HTR2A (0.46) | HTR2AHTR7 | |
| SCHEMBL29688909 | 0.94 | HTR2A (0.46) | HTR2AHTR7 | |
| SCHEMBL20135091 | 0.94 | HTR2A (0.46) | HTR2AHTR7 | |
| SCHEMBL20135614 | 0.88 | JAK1 (0.51) | JAK1HTR2ADRD2 | |
| SCHEMBL20135612 | 0.88 | JAK1 (0.51) | JAK1HTR2ADRD2 | |
| SCHEMBL20135282 | 0.85 | HTR2A (0.39) | HTR2AHTR7 | |
| SCHEMBL29688529 | 0.85 | HTR2A (0.39) | HTR2AHTR7 | |
| SCHEMBL20135284 | 0.85 | HTR2A (0.39) | HTR2AHTR7 | |
| SCHEMBL20135346 | 0.85 | RBP4 (0.42) | HTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | JAK1 438/4885HTR2A 3616/4885HTR7 3585/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | JAK1 355/4885HTR2A 3803/4885HTR7 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.